Vaxcyte, Inc. announced that it has progressed to Stage 2 of its Phase 2 infant study for the VAX-31 pneumococcal conjugate vaccine after a review of Stage 1 safety and tolerability data. VAX-31 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback